About Us

Cancer is fierce,
and so is our desire to beat it.

Meet the team that's taking on cancer.

Innovative design.
Endless Drive.

We’re bringing together medical physics, nuclear medicine and radiotherapy in new ways to shift the paradigm of cancer care. Our belief in the difference we can make knows no bounds.

Our Vision

To reveal cancer as never before and beat it for everyone, everywhere.

Our Mission

To create a machine that combines biotargeting with radiation and enable the first-ever systemic reach for radiotherapy for patients with any stage of cancer.

To reveal cancer as never before and beat it for everyone, everywhere.

To create a machine that combines biotargeting with radiation and enable the first-ever systemic reach for radiotherapy for patients with any stage of cancer.

The Beginning

Invention of BgRT

When co-founder Akshay Nanduri visited long-time friend, Sam Mazin at Stanford University, they discussed the possibility of using cancer’s own biology to see and treat multiple tumors at the same time – an idea that would soon become a reality.

It's Official!

RefleXion is born

Just a short time after discussing the idea, Sam Mazin and Akshay Nanduri officially formed RefleXion Medical, a privately-held biotargeting oncology company headquartered in Hayward, CA.

Clinical Evidence

First peer-reviewed publication

RefleXion publishes first paper in Medical Physics, the official journal of the American Association of Physicists in Medicine, that describes the RefleXion machine concept and the original BgRT approach for simulated lung and prostate cancers. It established the foundation for RefleXion’s clinical development program.

Growth

Funding the dream

RefleXion Medical successfully raised $11.6 million in Series A financing led by Paris-based Sofinnova Partners and joined by Pfizer Venture Investments (PVI), and Venrock.

FDA Clearance

RefleXion X1 Available for Sale

The RefleXion X1 receives clearance for SRS, SBRT and IMRT. This represents an important milestone for RefleXion on the journey to BgRT.

Further Investment

Raising Equity

RefleXion raises $100 million in equity capital following the FDA clearance for the RefleXion X1. Led by PSP, one of Canada’s largest pension fund investors, this financing round positions RefleXion for commercial growth.

Just the Beginning

First Commercial Sale

RefleXion announces the first X1 sale for cancer treatment at a world renowned cancer center located in Northern California.

psp logo

 

 

 

 

 

 

 

 

 

Significant innovation in localized cancer treatment

With a bold mission and the drive to build a high-performing business, RefleXion captured the interest of blue-chip investors, all committed to advancing a new modality in cancer care, especially for stage-four cancer patients.

To date, RefleXion has raised nearly $300M from premier investment firms including PSP Investments, TPG Growth / The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, and global pharmaceutical leaders, Pfizer Ventures, Johnson & Johnson Innovation, and Oxford Capital.

The National Cancer Institute (NCI) also provided grant funding through its Small Business Innovation Research (SBIR) Program.

Feedback
and
Inquiries.

Let us tell you more.

Contact Us

Sign up for our
latest news and information.

Stay up to date.

Sign Up